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PTEN is a lipid phosphatase that antagonizes the PI3K/AKT pathway and is recognized as a
major dose-dependent tumor suppressor. The cellular mechanisms that control PTEN levels
therefore offer potential routes to therapy, but these are as yet poorly defined. Here we
demonstrate that PTEN plays an unexpected role in regulating its own stability through the
transcriptional upregulation of the deubiquitinase USP11 by the PI3K/FOXO pathway, and
further show that this feedforward mechanism is implicated in its tumor-suppressive role, as
mice lacking Usp11 display increased susceptibility to PTEN-dependent tumor initiation,
growth and metastasis. Notably, USP11 is downregulated in cancer patients, and correlates
with PTEN expression and FOXO nuclear localization. Our findings therefore demonstrate
that PTEN-PI3K-FOXO-USP11 constitute the regulatory feedforward loop that improves the
stability and tumor suppressive activity of PTEN.
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PTEN (phosphatase and tensin homolog) negatively reg-ulates the highly oncogenic PI3K/AKT pathway throughdephosphorylation of phosphoinositide-3,4,5-triphosphate
(PIP3)1,2. Loss of PTEN function leads to a potent upregulation
of the PI3K/AKT pathway, which stimulates cell growth, pro-
liferation, migration, survival, and metabolism by phosphorylat-
ing the downstream signaling proteins such as FOXO
transcription factors3.
Many modeling efforts in Pten knockout mice have demon-
strated that PTEN functions in a haplo-insufficient manner.
Notably, the analysis of a series of hypomorphic Pten mouse
models has revealed that even subtle reductions in PTEN dosage
lead to an increased cancer susceptibility and higher rates of
tumor progression4,5. These observations have inspired a new
‘continuum model for tumor suppression’ that integrates and
updates Knudson’s two-hit theory6,7. Furthermore, recent studies
have shown that an increased PTEN dosage unexpectedly results
in viable mice displaying a tumor-resistant, anti-Warburg meta-
bolic state8,9, implying that PTEN elevation may potentially
represent a generally therapeutic approach in cancer. Intriguingly,
whereas less than 5% of the sporadic breast tumors harbor PTEN
mutations10, a loss of PTEN protein immunoreactivity is found in
nearly 40%11. Moreover, only 25% of cancer patients portray a
correlation between the loss of PTEN protein and its mRNA
level12. These data suggest that post-translational regulation of
PTEN may contribute substantially to the development of human
cancer.
Researchers have begun to identify the players in these post-
translation processes. Recent studies have shown that the
ubiquitin-proteasome system (UPS) is essential for the down-
regulation of PTEN, and it has been proposed that the E3 ubi-
quitin ligases NEDD4-1, XIAP, WWP2, and CHIP mediate PTEN
poly-ubiquitination and degradation13–16. In contrast, HAUSP,
ataxin-3, USP13, and OTUD3 have all been identified recently as
PTEN deubiquitinases (DUBs): HAUSP specifically removes the
mono-ubiquitination of PTEN for its nuclear export17, ataxin-3
regulates PTEN at the transcriptional level18, and USP13 and
OTUD3, which predominantly reside in the cytoplasm, affect
cytosolic PTEN stability in a breast cancer-specific context19,20.
While it is not surprising that such an important tumor sup-
pressor is controlled by multiple DUBs, the physiological context
of PTEN stability is yet to be addressed.
Ubiquitin-specific protease 11 (USP11, also known as UHX1)
was originally identified as one of the X-linked retinal disorder
genes at Xp11.2321, although it is worth noting that a common
deletion within the USP11 interval had been observed earlier in
ovarian cancer22. X-linked tumor suppressor genes are of parti-
cular interest because loss-of-heterozygosity (LOH) or mutation
of a single allele can in effect functionally silence a gene23. As a
deubiquitinase, USP11 is likely to have multiple protein sub-
strates, such as p53, PML, and IκBα24–26. However, there is
insufficient direct genetic evidence to define its precise role with
the specificity required to target proteins of USP11 involved in
tumorigenesis.
In this study, we report the identification of a PTEN feedfor-
ward mechanism and define both its critical role in tumorigenesis
and its clinical relevance to patients.
Results
USP11 antagonizes PI3K activity by upregulating PTEN. In
order to identify DUBs that regulate the PI3K/AKT pathway, we
first screened a synthetic siRNA library, targeting mouse DUBs in
mouse embryonic fibroblasts (MEFs), and examined the rates of
AKT phosphorylation (pS473 and pT308) using AlphaScreen
assays (Supplementary Fig. 1a). We subsequently assessed the
cellular levels of both PIP3, which is mainly found on the leading
edges of filopodia and lamellipodia27, and PTEN protein in cells
expressing potential positive DUB shRNA vectors (Supplemen-
tary Fig. 1b, c). After target deconvolution of the observed hits, we
identified USP11 as a potent inhibitor of the PI3K/AKT pathway
on the basis of PTEN protein accumulation (Fig. 1a, b).
We then determined the binding between endogenous USP11
and PTEN by performing reciprocal immunoprecipitations
(Fig. 1c) and confirmed their physical interaction by utilizing
glutathione S-transferase (GST) pull-down assays (Supplemen-
tary Fig. 2a). Notably, wild-type (WT) USP11 deubiquitinated
PTEN in vivo and in vitro, whereas the catalytically inactive
USP11 C318S (CS) mutant, which could still bind to PTEN,
exerted a dramatically diminished ability to deubiquitinate PTEN,
and even exhibited a more heavy ubiquitinating effect (Fig. 1d
and Supplementary Fig. 2b–e). Overexpression of WT, but not
C318S, USP11 also increased PTEN levels (Fig. 1e). To further
determine whether USP11 can regulate the stability of PTEN
protein, we next examined endogenous PTEN protein levels in
the presence of cycloheximide (CHX), an inhibitor of protein
synthesis. Importantly, the stability of endogenous PTEN protein
in NB4 human APL cells (t1/2 ≈ 12 h) was significantly reduced
upon the downregulation of USP11 (t1/2 < 4 h) (Fig. 1f).
Other DUBs, including USP13 and OTUD3, were recently
found to stabilize PTEN protein through deubiquitination19,20.
We then compared the PTEN-stabilizing ability of USP11,
USP13, and OTUD3 by performing side-by-side assays. We first
examined the interactions among endogenous PTEN, USP11,
USP13, and OTUD3. PTEN and DUBs were readily co-
immunoprecipitated with each other; however, USP11, USP13,
and OTUD3 were not associated with each other (Supplementary
Fig. 3a). Overexpression and knockdown experiments both
revealed that USP11, USP13, and OTUD3 exhibit a synergistic
effect on PTEN expression (Supplementary Fig. 3b, c). The
ectopic expression of USP11 in PTEN-proficient human prostate
cancer cell line DU145 depleted of USP13 or OTUD3 still
upregulated PTEN (Supplementary Fig. 3d, e), suggesting that
USP11 could be a more potent regulator of PTEN than other
DUBs in our assays. Notably, the destabilization of PTEN in the
nucleus upon the depletion of USP11 was more significant than
that upon the loss of USP13 or OTUD3 (Supplementary Fig. 3f–i),
suggesting that USP11, but not USP13 or OTUD3, regulates
PTEN expression in the nucleus. Furthermore, our analysis of
TCGA datasets from cBioPortal (www.cbioportal.org) and
Kmplot (http://kmplot.com/analysis/)28–31 indicates that the
clinical significance of USP11 is more significant than that of
USP13 or OTUD3 (Supplementary Fig. 4).
We have previously demonstrated that HAUSP specifically
removes the mono-ubiquitination of PTEN for its nuclear
export17. We, therefore, tested whether USP11 could remove
the mono-ubiquitination of PTEN in the nucleus. While HAUSP
removed the mono-ubiquitination of PTEN, USP11 did not
abolish the mono-ubiquitination of PTEN (Supplementary
Fig. 3j), suggesting that USP11 represents a unique DUB that
de-polyubiquitinates and stabilizes PTEN in the nucleus.
To further test the propensity of USP11 to antagonize PI3K
activity via PTEN, we depleted Usp11 by RNA interference in
Pten+/+ and Pten-/- MEFs. Insulin stimulation led to acute AKT
phosphorylation, as well as an increase of PIP3 in Usp11-silenced
cells to levels higher than those observed in Pten+/+ control cells,
but not Pten-/- MEFs, which implies that USP11 has a PTEN-
dependent PI3K inhibitory function (Fig. 1g, h). Similar results
were observed upon the stimulation of serum, IGF-1, or EGF.
Taken together, these results suggest that USP11 reverses poly-
ubiquitination of PTEN, stabilizes PTEN protein, and thereby
suppresses the activation of the PI3K/AKT pathway.
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Usp11 loss induces cell growth, motility, and metabolism.
To examine the biological functions of USP11 in vivo, we
derived mice from a cryopreserved knockout mouse sperm
(TF2623; Taconic Biosciences) and an oocyte donor. The gene-
targeting cassette contained lacZ, the neomycin resistance gene
(neoR), and had been integrated into exons 3–12 of Usp11 to
generate a dysfunctional allele that we named Usp11- (Supple-
mentary Fig. 5a). As Usp11 is an X-linked gene, hemizygous male
(Usp11-/Y) embryos were sufficient to create a Usp11 loss-of-
function mutation (Supplementary Fig. 5a, b). The levels of
endogenous PTEN protein (but not mRNA) were reduced, and
the phosphorylation rates of AKT and its downstream targets,
such as FOXO1 and AS160 (or TBC1D4), were enhanced in
primary MEFs isolated from Usp11-/Y embryos compared to
WT cells (Supplementary Fig. 5b, c). Likewise, PTEN immuno-
precipitates showed a heavier poly-ubiquitination pattern in
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Usp11-/Y MEFs (Supplementary Fig. 5d). It is also worth noting
that the loss of Usp11 had no significant effect on the subcellular
compartmentalization of PTEN (Supplementary Fig. 5e–g).
Given the tumor-suppressive roles of PTEN3,32, we speculated
that the loss of Usp11 might promote a variety of tumorigenic
processes. Indeed, primary Usp11-/Y MEFs showed a higher
growth rate than their WT counterparts (Fig. 2a, b). The
transformation efficiency of adenovirus E1a in combination with
the activated Ha-ras, SV40 large T antigen (T-Ag) or p16INK4a
and p19Arf shRNAs, was also significantly higher in Usp11-
deficient cells than in WT cultures (Fig. 2c). In vivo mouse
allograft generation with these transformed cells confirmed the
critical tumor-suppressive function of USP11 (Fig. 2d). When
Usp11-/Y MEFs were subjected to wound-healing assays, Usp11-/Y
MEFs were found to close the wound more rapidly than WT cells
(Fig. 2e). It is also noted that the increased cell motility upon
Usp11 loss was accompanied by the upregulation of matrix
metalloproteinases (MMPs), including gelatinase Mmp9 and
collagenase Mmp13 (Fig. 2f). Furthermore, Usp11-deficient cells
showed higher rates of glucose uptake, lactate production, and
glutamine consumption than did their WT counterparts (Fig. 2g).
In contrast, cells overexpressing USP11 exhibited impaired
glucose and glutamine metabolism, accompanied by reduced
expression of GLUT1 (glucose transporter type 1) in the plasma
membrane fraction (Fig. 2h, i).
Usp11 knockout enhances tumor progression in TRAMP mice.
The phenotype of Usp11 knockout mice has not been reported to
date. Usp11- mice (Usp11-/Y and Usp11-/-) were viable and born at
the expected Mendelian frequency. As decreasing PTEN levels
correlate with increased initiation and progression of prostate
tumors in the mouse5,33, we assessed the role of USP11 in
prostate tumorigenesis in vivo. Notably, Usp11-/Y mice at
11 weeks of age displayed significantly enlarged prostate lobes
and increased prostatic epithelial cell proliferation (Fig. 3a–c). We
further investigated the consequences of loss of Usp11 in a mouse
model of prostate cancer. To this end, we crossed our Usp11-/Y
mice with TRAMP (transgenic adenocarcinoma mouse prostate)
mice, in order to drive the prostate-specific expression of SV40 T
antigen (Ag)34. The clinical relevance of the use of SV40 T Ag,
which induces oncogenic progression by binding and inactivating
Trp53 and Rb1 tumor suppressor genes35, is supported by pre-
vious data showing the loss of p53 and Rb in human prostate
cancer36,37. Moreover, while the TRAMP mouse model is
designed to induce the development of prostate tumors, LOH of
Pten in TRAMP mice led to a significantly increased rate of tumor
development, with a subsequent decrease in overall survival38. To
study the early effects of Usp11 ablation in the prostate, TRAMP
mice of differing Usp11 backgrounds were sacrificed at 10 weeks
of age and histopathological analysis was performed. TRAMP;
Usp11-/Y mice showed a significantly higher rate of high-grade
prostatic intraepithelial neoplasia (HG-PIN) than age-matched
TRAMP;Usp11+/Y mice (Fig. 3d, e).
To further analyze the effects of loss of Usp11 on prostate
carcinoma in TRAMP mice, we followed cohorts of TRAMP;
Usp11+/Y and TRAMP;Usp11-/Y mice by magnetic resonance
imaging (MRI) analysis. MRI analysis revealed the presence of
larger tumor masses in the prostates of 20-week-old TRAMP;
Usp11-/Y mice than in age-matched TRAMP;Usp11+/Y cohorts
(Fig. 3f). Histological examination by hematoxylin and eosin
staining revealed severe malignant progression in TRAMP;
Usp11-/Y mice, whereas the prostate glands of age-matched
TRAMP;Usp11+/Y mice were preserved and the tissue showed a
PIN phenotype (Fig. 3g). It is worth noting that TRAMP;Usp11-/Y
mice exhibited lower levels of PTEN expression and higher
phosphorylation levels of AKT than TRAMP control mice
(Supplementary Fig. 6). Smooth muscle actin (SMA) staining
revealed a highly penetrant invasive prostatic adenocarcinoma in
TRAMP;Usp11-/Y mice as compared to age-matched TRAMP;
Usp11+/Y mice (Fig. 3h). Furthermore, multiple tumor nodules
metastasized to lymph nodes in TRAMP;Usp11-/Y mice (~80%
incidence), which was seen at a far lower incidence (< 20%) in
TRAMP;Usp11+/Y mice (Fig. 3i). These results validate USP11 as
a potential X-linked tumor-suppressive factor for prostate cancer
initiation, progression, and metastasis.
USP11-mediated tumor suppression is PTEN dependent. In
prostate cancer, the ERG gene is frequently translocated to the
TMPRSS2 promoter region, with the resulting TMPRSS2-ERG
fusion protein expressed in ~50% of human prostate cancers39,40.
As aberrant ERG expression collaborates with Pten haplo-
insufficiency to promote cancer progression41,42, we assessed
whether USP11 loss would affect ERG-dependent cellular pro-
cesses. Depletion of USP11 enhanced growth, invasion, and glu-
cose and glutamine metabolism in ERG-negative 22Rv1 human
prostate cancer cells stably overexpressing ERG (22Rv1ERG)
(Supplementary Fig. 7a–c).
To further study the contribution of USP11 DUB activity to
USP11-mediated tumor suppression, we used a human haploid
cancer cell line, HAP1, in which the single allele of USP11 had
been knocked out using CRISPR/Cas9 technology. Notably, in
HAP1 cells knocked out for USP11, reintroduction of WT, but
not catalytically inactive CS, USP11 resulted in a decreased cancer
cell growth, invasion, and glucose and glutamine metabolism
(Fig. 4a–c). Similar results were observed in Usp11 null MEFs
(Supplementary Fig. 7d–f).
Fig. 1 USP11 reduces PIP3 levels by deubiquitinating and stabilizing PTEN. a The screen scheme for the DUB library. b Validation of an RNAi screen in (a).
MEFs expressing two independent Usp11 shRNAs were subjected to AlphaScreen assays (top, left) and immunoblotting (IB) (bottom, left). The levels of
PIP3 in MEFs expressing Usp11 shRNA were evaluated using an IF (top, middle) and PIP3 Mass ELISA assays (bottom, middle). Lysates and total RNAs
from PTEN-proficient DU145 cells and PTEN-deficient PC3 cells complemented with PTEN expressing USP11 shRNAs were subjected to IB (top, right) and
RT-qPCR (bottom, right). Scale bars, 10μm. n= 3. Error bars represent ± SEM. p Value was determined by Student’s t test (n.s., non-significant; *p < 0.05;
**p < 0.01). c Lysates from DU145 cells were immunoprecipitated (IP) without (Mock) or with anti-PTEN (top) or anti-USP11 (bottom) antibody and
subjected to IB. # indicates heavy chain of IgG. d Lysates from 293T cells transfected as indicated and treated with 10 μMMG132 for 4 h were IP with anti-
Myc–PTEN, and the resulting immunoprecipitates were subjected to IB. # indicates the heavy chain of IgG. HA-Ub, HA-tagged ubiquitin. e Lysates from
DU145 cells overexpressing wild-type (WT) or catalytically inactive C318S (CS) mutant of USP11 were subjected to IB. f Lysates from NB4 cells expressing
USP11 shRNA and treated with cycloheximide (CHX, 100 μg ml−1) for the indicated times were subjected to IB (top). PTEN protein levels were quantified
by normalizing to the intensity of the actin band (bottom). n= 3. Error bars represent ± SEM. p Value was determined by ANOVA (*p < 0.05). g IF
analysis of PIP3 in Pten+/+ and Pten-/- MEFs expressing Usp11 shRNAs starved for 8 h and stimulated with 100 nM insulin for 5 min. Arrowheads indicate
the accumulation of PIP3 at the leading edges of membrane projections. Scale bars, 10μm. h Lysates from Pten+/+ and Pten-/- MEFs expressing
Usp11 shRNAs, starved for 8 h and stimulated with serum for 10min or 100 nM insulin, 100 ngml−1 IGF-1, or 25 ngml−1 EGF for 5 min, were subjected to
IB. MEFs, mouse embryonic fibroblasts; RT-qPCR, real-time quantitative reverse transcription PCR
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Next, we tested whether USP11 functions as a tumor
suppressor through PTEN regulation. Forced expression of
USP11 inhibited the growth of PTEN-complemented PTEN null
PC3 human prostate cancer cells (PC3 PTENWT)43, but not PC3
cells expressing the control vector (PC3 PTEN-/-) (Fig. 4d).
Overexpression of USP11 also diminished the invasion ability of
PC3 PTENWT, but not PC3 PTEN-/-, cells (Fig. 4e). USP11
overexpression likewise led to a decrease in glucose uptake, lactate
production, and glutamine consumption in PC3 PTENWT cells,
while no substantial difference was observed in PC3 PTEN-/- cells
(Fig. 4f). Conversely, knocking down USP11 enhanced the cell
growth, invasion, and energy metabolism of PC3 PTENWT cells
but not PC3 PTEN-/- cells (Fig. 4g–i), suggesting that USP11
exerts a PTEN-dependent tumor-suppressive function.
USP11 is reduced and correlates with PTEN in human cancers.
The tumor-suppressive role of USP11 identified above prompted
us to evaluate USP11 expression in cancer patients. Interestingly,
a recent transcriptome profiling analysis of human prostate
cancer44,45 revealed that USP11 transcript expression was
downregulated in primary prostate tumors, and its reduction was
closely associated with tumor aggressiveness (Fig. 5a). Down-
regulation of USP11 was also observed in human breast tumors46
(Fig. 5b). We further confirmed the clinical significance of USP11
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downregulation through a cancer patient survival analysis drawn
from another available database (http://kmplot.com/analysis/)31
(Fig. 5c), which suggests that its repression may impact neoplastic
malignancies and clinical outcomes.
To determine the clinical relevance of PTEN regulation by
USP11, we studied tumor tissue microarrays (TMAs) of human
prostate cancer and triple-negative breast cancer (TNBC) samples.
First, the fluorescence in situ hybridization (FISH) analysis of
PTEN DNA status revealed that in our prostate and TNBC TMAs,
85.3% (99 of 116) and 83.5% (86 of 103) had two copies of PTEN,
respectively (while 13 and 16.5% were hemizygous, 1.7 and 0%
exhibited homozygous loss) (Fig. 5d). We then examined whether
USP11 expression levels correlated with PTEN protein levels in
the TMAs of 99 prostate cancer and 86 TNBC cases presenting
two copies of the PTEN gene. Notably, an immunohistochemical
analysis of human prostate tumors demonstrated a statistically
significant positive correlation (r= 0.385, p= 0.012) between
USP11 and PTEN protein levels, as 72.9% (35 of 48) of the tumors
with low USP11 expression also exhibited low PTEN expression
(Fig. 5e). Similarly, a highly positive correlation (r= 0.435, p=
0.008) was observed between USP11 and PTEN protein levels in
TNBC samples, as 68.1% (32 of 47) of tumors with low USP11
expression also displayed low PTEN expression. Taken together,
these results suggest that in a significant fraction of human
malignant tumors, USP11 is downregulated, and a reduced USP11
expression can function as a mechanism of PTEN inactivation in
the absence of PTEN genomic loss.
USP11-mediated cell density-dependent PTEN regulation. To
date, great progress has been made in understanding the cellular
functions of PTEN, but the mechanisms of its physiological
regulation have not been fully established. Normal cells generally
cease proliferation upon reaching confluence, a phenomenon
referred to as cell contact inhibition;47 however, the activation of
oncogenes and the inactivation of tumor suppressor genes can
prevent contact inhibition48. We thus tested the effect of cell
density on USP11-mediated PTEN regulation. Intriguingly,
PTEN expression was greatly increased in both primary and
transformed MEFs grown at a high cell density (Fig. 6a). The
observed elevation of PTEN at a high cell density was not due to
an increased rate of Pten transcription, as Pten mRNA remained
the same regardless of cell density (Fig. 6b). Moreover, the PTEN
protein turnover rate was higher in sparse cells, and endogenous
PTEN immunoprecipitates showed a heavier poly-ubiquitination
pattern in cells with a low density than in those with a high
density (Fig. 6c, d). We next tested the effect of cell density on
USP11-mediated PTEN regulation. Surprisingly, the mRNA levels
of USP11, but not of any other known PTEN DUBs, including
HAUSP (also known as USP7), USP13, and OTUD317,19,20, were
far higher in dense cells than in sparse cells (Fig. 6e, f). By
characterizing the outcomes by growing sparse cultures in con-
ditioned media from the dense cultures, we verified that the
observed increases in PTEN and USP11 levels were not likely
associated with autocrine effects, build-up of metabolites, or
changes in pH in culture media (Supplementary Fig. 8a). More
importantly, the depletion of USP11 impaired high density-
induced PTEN upregulation (Fig. 6g), suggesting that cell density
controls the physiological levels of PTEN protein, at least in part,
through the transcriptional modulation of USP11.
FOXO acts as a key transcriptional activator of USP11. Several
lines of evidence have demonstrated that in many genes, density-
driven cellular mechanisms induce distinct waves of transcrip-
tional activation49,50. To investigate how USP11 is tran-
scriptionally regulated by cell density, we utilized the TRANSFAC
8.3 program and chromatin immunoprecipitation (ChIP)-
sequencing databases available via the UCSC Genome Browser
(http://genome.ucsc.edu) to uncover the transcription factors
bound on the USP11 promoter. Among multiple candidates, we
were particularly interested in FOXO, because it is known to be a
key player in high density-induced gene activation49 (Fig. 6a and
Supplementary Fig. 8b, c). Under high-density conditions two
independent Foxo1 shRNAs indeed impaired the elevation of
protein and mRNA levels of USP11, but not other DUBs,
including HAUSP, USP13, and OTUD3 (Fig. 6h and Supple-
mentary Fig. 8d). Likewise, Foxo1 knockdown significantly
decreased the luciferase activity of a USP11 promoter reporter
construct, pUSP11-Luc, whereas the overexpression of FOXO1, 3,
or 4 strongly promoted the transcriptional activation of USP11
(Fig. 6i and Supplementary Fig. 8e). It is also noted that mutation
of the FOXO-binding site within the USP11 promoter diminished
the effect of FOXO1 (Fig. 6j and Supplementary Fig. 8c). Endo-
genous FOXO1 protein was bound to a region (~80 bp) encom-
passing a critical FOXO-binding site within Usp11 promoter, and
the binding of FOXO1 was significantly enhanced by a high cell
density (Fig. 6k), suggesting that FOXO proteins could directly
activate the transcription of USP11. More importantly, ablation of
Foxo1 impaired high density-induced PTEN upregulation in pri-
mary MEFs (Fig. 6l), suggesting that FOXO plays an important
role in the physiological regulation of PTEN expression.
The activation of FOXO can be controlled by acetylation, and
resveratrol (3,4′,5-trihydroxystilbene) induces SIRT1-mediated
deacetylation of FOXO51,52 (Fig. 7a). We, therefore, tested
whether resveratrol induces USP11 transcription through
SIRT1/FOXO. Resveratrol increased USP11 protein and mRNA
levels, but this effect was diminished by the knockdown of SIRT1
(Fig. 7b and Supplementary Fig. 8f). Knocking down FOXO1 si-
milarly reduced the effects of resveratrol on USP11 transcriptional
activation (Fig. 7c and Supplementary Fig. 8g), suggesting that
resveratrol promotes USP11 expression, at least in part, through
Fig. 2 Loss of Usp11 increases cell proliferation, motility, and metabolism. a Growth curves of primary wild-type (Usp11+/Y) and Usp11-/Y MEFs. n= 3.
b Colony-formation efficiency of primary Usp11+/Y and Usp11-/Y MEFs (left). The number of colonies per well was counted (right). n= 3. c Representative
plates stained with crystal violet in transformation assays of Usp11+/Y and Usp11-/Y MEFs with the indicated oncogenes are shown (top). Quantification of
the number of transformed foci is also shown (bottom). n= 6. d Representative images of allograft tumors of Usp11+/Y and Usp11-/Y MEFs transformed by
E1a+Ha-ras oncogenes (top). Lysates from the tumors were subjected to IB (middle). Tumor volumes at different days were measured (bottom). n= 6,
p value was determined by ANOVA (***p < 0.001). e Representative images of wound-healing assays of Usp11+/Y and Usp11-/Y MEFs at time points t= 0,
12, and 24 h in the presence of mitomycin C (5 μg ml−1) after wound introduction (left). The percentage of wound closure at the indicated time points was
determined by the ImageJ 1.46r software (right). Scale bars, 100μm. n= 3. f MMP family member gene enrichment signature from (e) by microarray. n= 3.
Heatmap colors represent the relative mRNA expression as indicated in the color key. g The rates of glucose uptake, lactate production, and glutamine
consumption of Usp11+/Y and Usp11-/Y MEFs were measured and normalized to cell number. n= 3. h The rates of glucose uptake, lactate production, and
glutamine consumption of MEFs overexpressing USP11 were measured and normalized to cell number. n= 3. i Cytosolic and plasma membrane fractionation
of GLUT1 in MEFs overexpressing USP11 treated with insulin (0.5 μgml−1) for the indicated times is shown. # indicates nonspecific band. Error bars
represent ± SEM. p Value was determined by Student’s t test (*p < 0.05; **p < 0.01; ***p < 0.001). IB, immunoblotting; MEFs, mouse embryonic fibroblasts
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the SIRT1/FOXO pathway. Notably, resveratrol appreciably
elevated the PTEN levels, mainly through increasing the stability
of PTEN protein (Fig. 7d). It should be noted that resveratrol has
been shown to regulate the PTEN/AKT pathway through an
androgen receptor (AR)-dependent mechanism53. However, our
data indicate that the resveratrol-associated elevation of PTEN
protein levels is unlikely to be caused by AR-mediated
transcription (Supplementary Fig. 8h, i). More importantly, the
elevation of PTEN protein levels by resveratrol was reduced in
USP11-depleted cells (Fig. 7e, f), suggesting that resveratrol
upregulates PTEN protein expression via the activation of USP11.
We also found that the overexpression of active nuclear mutants
of FOXO (FOXO1T24A,T256A,S319A or FOXO3T32A,S253A,S315A),
which lacked AKT phosphorylation sites54, led to a marked
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increase in the activity of the USP11 promoter (Fig. 7g). To further
evaluate whether FOXO1 nuclear localization can activate USP11
expression, we treated cells with a specific inhibitor of FOXO1
nuclear export, psammaplysene A (PsA), which is a natural product
of the marine sponge Psammaplysilla sp55–58. Treatment with PsA
promoted nuclear retention of FOXO1 as compared to vehicle
(Fig. 7h and Supplementary Fig. 8j). Notably, PsA treatment also
increased USP11 and PTEN expression levels in a FOXO1-
dependent manner (Fig. 7i), suggesting that the enhancement of
FOXO nuclear localization leads to substantial activation of USP11
expression.
Next, we sought to determine the clinical relevance of USP11
regulation by FOXO in patients. Importantly, an immunohisto-
chemical analysis of human prostate and TNBC tumors
demonstrated a statistically significant positive correlation
between FOXO nuclear localization and USP11 expression
(Fig. 7j; p= 0.00064 and p= 0.00028, respectively).
PTEN auto-regulation by a signaling feedforward mechanism.
Because PI3K/AKT-mediated phosphorylation of FOXO results
in its nuclear exclusion and inhibition of transcriptional activ-
ity59, and FOXO activation strongly promotes USP11 transcrip-
tion, we speculated that PTEN might be able to regulate itself
through a PTEN-PI3K-FOXO-USP11 auto-regulatory loop. We
first observed that protein and mRNA levels of USP11, but not
any other known PTEN DUBs (such as HAUSP, USP13, and
OTUD3), were markedly lower in isogenic PTEN-null (PTEN-/-)
HCT116 colon carcinoma cells compared to WT parent
(PTEN+/+) or heterozygous (PTEN+/-) cells (Fig. 8a, b). A luci-
ferase reporter assay revealed that the loss of PTEN similarly
inhibited the activity of the USP11 promoter (Fig. 8c), and
notably, the binding of FOXO1 to a region (~80 bp) encom-
passing a critical FOXO-binding site within USP11 promoter was
impaired in PTEN-deficient cells (Fig. 8d). In agreement with
these in vitro results, USP11 but not any other known PTEN
DUB (including HAUSP, USP13, and OTUD3) has been shown
to be downregulated in Pten knockout mouse prostates when the
incidence of PIN and the increase of cell proliferation are low43,60
(Fig. 8e), implying a key role for PTEN in the control of USP11
expression in vivo.
Next, to elucidate the contribution of the PTEN/PI3K/AKT
signaling pathway to USP11 regulation, we tested USP11
expression upon the blockade of the PI3K/AKT pathway.
Notably, the inhibition of PI3K by BKM120 or LY294002
markedly increased USP11 protein and mRNA levels, accom-
panied by the upregulation of PTEN (Fig. 8f and Supplemen-
tary Fig. 9a). Similar observations were made after treatment
with the AKT inhibitor MK-2206 (Supplementary Fig. 9b).
Conversely, the treatment with the potent PTEN inhibitor
VO-OHpic4,61,62 led to the reduction of USP11 expression,
accompanied by the downregulation of PTEN (Fig. 8g). It is
also worth noting that treatment with the proteasome inhibitor
MG132 did not result in a further increase in the PTEN protein
levels induced by the inhibition of PI3K with BKM120 or
ablation of p85, the regulatory subunit of PI3K (Fig. 8h, i),
which suggests that the PTEN regulatory loop is mediated by
the ubiquitin–proteasome pathway. We further examined the
effects of the phosphatase activity of PTEN on the regulation of
USP11 using PTEN null cells complemented with either WT or
phosphatase-inactive PTEN (C124S or G129E)63. Expression of
PTENC124S or PTENG129E phosphatase-inactive mutants led to
significant reductions in the levels of protein, mRNA, and
promoter activity of USP11 (Fig. 8j and Supplementary Fig. 9c,
d). Taken together, these results suggest that PTEN-PI3K/AKT-
FOXO and USP11-PTEN integrate into a PTEN feedforward
signaling network (Fig. 8k).
Discussion
Our findings allow us to reach several relevant conclusions.
First, we have identified the X-linked tumor-suppressor USP11
as an important physiological PTEN DUB that antagonizes the
PI3K/AKT signaling pathway. X-linked tumor suppressor genes
are of potential significance in tumorigenesis, as LOH or muta-
tion of a single allele can in effect functionally silence a gene23,
and the skewed X inactivation may select toward or against dis-
ease64. Our Usp11 knockout strategy supports USP11 as a critical
X-linked tumor suppressor that deubiquitinates and stabilizes
PTEN. Further, our analysis of cancer patients suggests that
reduced USP11 expression can be a mechanism of PTEN inac-
tivation (or reduced expression) in the absence of PTEN deletion.
In addition to USP11, HAUSP, USP13, and OTUD3 have all been
recently identified as PTEN DUBs. HAUSP is mainly localized in
the nucleus and specifically removes the mono-ubiquitination of
PTEN to affect its nuclear exclusion17, while USP13 and OTUD3,
which predominantly reside in the cytoplasm or the plasma
membrane, reverse the poly-ubiquitination of cytosolic or
membrane-bound PTEN protein in a breast cancer-specific
context19,20. In contrast, here we report that USP11 regulates
PTEN poly-ubiquitination and protein stability in both the
cytoplasm and nucleus, and in both cancerous (as an important
modifier of PTEN levels/activity in prostate cancer) and non-
cancerous contexts (as a vector through which cell density con-
trols the physiological dosage of PTEN protein). These findings
reveal the latest picture of PTEN DUBs’ behaviors (Supplemen-
tary Fig. 10), and it will be interesting to further determine their
synergism to control PTEN and tumorigenesis in vivo.
Fig. 3 Usp11 ablation promotes tumor growth and metastasis in TRAMP mice. a Lysates from anterior prostate (AP) of 11-week-old Usp11+/Y and Usp11-/Y
mice were subjected to immunoblotting. b Prostate tissue weight relative to body weight (BW) of 11-week-old Usp11+/Y (n= 8) and Usp11-/Y (n= 8) mice.
VP, ventral prostate; AP, anterior prostate; DLP, dorsal-lateral prostate. c Ki-67-stained sections of anterior prostate lobes isolated from 11-week-old
Usp11+/Y and Usp11-/Y mice (left). Quantification of the number of Ki-67-positive cells is shown in right. Green scale bars, 75μm; yellow scale bars, 150μm.
d H&E-stained sections of dorsal-lateral prostate lobes isolated from 10-week-old TRAMP;Usp11+/Y (n= 8) and TRAMP;Usp11-/Y (n= 6) (left).
Quantification of prostatic intraepithelial neoplasia (PIN) is shown in right. Scale bars, 75μm. e Ki-67-stained sections of anterior and ventral prostate lobes
isolated from 10-week-old TRAMP;Usp11+/Y (n= 8) and TRAMP;Usp11-/Y (n= 6) (left). Quantification of the number of Ki-67-positive cells is shown in the
right. Scale bars, 75μm. f MRI analysis of 20-week-old TRAMP;Usp11+/Y (n= 6) and TRAMP;Usp11-/Y (n= 6) mice (top), and quantification of prostate
tumor volume using an Oxirix Imaging software (bottom, left). Prostate tissue weight of 25-week-old TRAMP;Usp11+/Y and TRAMP;Usp11-/Y mice is also
shown (bottom, right). g Sections of prostate isolated from 25-week-old TRAMP;Usp11+/Y and TRAMP;Usp11-/Y mice stained with H&E and anti-SV40 T
Ag. Scale bars, 75μm. h Sections of prostate isolated from 25-week-old TRAMP;Usp11+/Y and TRAMP;Usp11-/Y mice stained with H&E and anti-smooth
muscle actin (SMA) (left). Percentage of invasive prostate carcinoma (CaP) in TRAMP;Usp11+/Y (n= 6) and TRAMP;Usp11-/Y (n= 6) mice is shown in the
right. Scale bars, 75μm. i Sections of lymph nodes isolated from 25-week-old TRAMP;Usp11+/Y and TRAMP;Usp11-/Y mice stained with H&E and anti-SV40
T Ag (left). Percentage of lymph node (LN) metastases in TRAMP;Usp11+/Y (n= 6) and TRAMP;Usp11-/Y (n= 5) mice is shown in the right. Scale bars,
75μm. Error bars represent ± SEM. p Value was determined by Student’s t test (*p < 0.05; **p < 0.01; ***p < 0.001). H&E, hematoxylin and eosin; MRI,
magnetic resonance imaging; TRAMP, transgenic adenocarcinoma mouse prostate
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Second, we have found that PTEN auto-regulates itself through
the PI3K-FOXO-USP11 feedforward loop to create a PTEN
“integrated circuit” that induces tumor suppression. It has been
widely reported that important signaling systems are not simple
linear pathways, but rather complex dynamic networks in which
crosstalks between many players are critical to cellular outcomes.
For instance, the p110 delta isoform of PI3K regulates PTEN
activity through RhoA-ROCK-dependent signaling65. Likewise,
activated PI3K has been shown to promote PTEN nuclear
exclusion through mTOR signaling66. While the precise con-
tribution of the PI3K/AKT pathway to the regulation of PTEN
protein expression (and hence tumorigenesis) is yet to be deter-
mined, our data provide compelling evidence of a PTEN reg-
ulation mechanism whereby a PTEN-PI3K-FOXO-USP11 auto-
regulatory loop regulates PTEN protein levels and activity.
Indeed, the genetic or pharmacological inhibition of PI3K
(through p85 deletion or BKM120 treatment) increases PTEN
protein expression, although these increases are blunted when the
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proteasome is inhibited. Furthermore, our results reveal that this
feedforward mechanism acts as a vector through which cell
density controls the physiological dosage of PTEN protein, and,
as a result, may enable cells, whether normal or cancerous, to
induce PTEN expression during the suppression of cellular pro-
liferation mediated by high density. Because a large fraction of
human solid tumors present the loss of only one PTEN allele10,32,
we propose that the increased PI3K/AKT activation observed
with reduced PTEN levels will lead to the cytoplasmic seques-
tration of FOXO, reduced USP11 expression, and further PTEN
degradation, which in turn sustains PI3K/AKT activation and
drives malignant growth in epithelial tissues with heterozygous
inactivation of PTEN. Thus, our findings provide a rationale for
cancer patient stratification based on whether the PTEN-PI3K-
FOXO-USP11 feedforward mechanism is ‘on’ or ‘off’, which will
optimize the personalized therapies by stabilizing PTEN protein
in those human cancers that do not exhibit a homozygous
(biallelic) loss of PTEN.
Methods
Mice. Usp11 knockout mice were obtained from a knockout mouse cryopreserved
sperm (TF2623, Taconic Biosciences) and an oocyte donor. The gene-targeting
cassette, containing lacZ/neoR, is integrated into exons 3–12 of Usp11, generating a
dysfunctional allele Usp11 that is named Usp11-. Mice were genotyped by PCR with
the following primers: WT, P1: 5′-GTCTGTCTGGGTTCCAGGTTC-3′ and P2:
5′-GCTGACCATGTAGTTCCAAGC-3′; Usp11-, P1 and P3: 5′-CCCTAG-
GAATGCTCGTCAAGA-3′. Sex determination was performed using the following
primers: Sry, 5′-CTGTACTCCAAAAACCAGCAAAG-3′; 5′-AGTAAGTAGG-
TAAGCTGCTGGTCGT-3′ and Myog (Myogenin), 5′-CTGTACTCCAAAAAC-
CAGCAAAG-3′; 5′-AGTAAGTAGGTAAGCTGCTGGTCGT-3′. To generate
TRAMP;Usp11-/Y compound mice, Usp11-/Y mice were crossed with TRAMP
transgenic mice (Jackson Laboratory). Experimental mice were euthanized at 10
and 25 weeks. At sacrifice, prostatic lobes were removed and weighed. Prostate and
lymph node tissues were fixed with 4% paraformaldehyde. Primers for genotyping
are TRAMP: 5′-GCGCTGCTGACTTTCTAAACATAAG-3′ and 5′-GAGCT-
CACGTTAAGTTTTGATGTGT-3′. All animal experiments in this study were
approved by and adhered to the guidelines of the MD Anderson Cancer Center
Animal Care and Use Committee.
Cells. Primary Usp11+/Y, Usp11-/Y, and Foxo1fl/fl MEFs were prepared from
embryos at 13.5 d of development (E13.5). Early-passage (P1) MEFs were used.
293 T, DU145, PC3, NB4, NIH-3T3, U2OS, MCF-10A, MDA-MB-231, MDA-MB-
157, HS578T, BT549, and MDA-MB-468 cell lines were obtained from ATCC
(Manassas, VA, USA). HCT116 PTEN+/+, HCT116 PTEN+/- (catalog number: HD
104–057), and HCT116 PTEN-/- (HD 104-004) cell lines and HAP1 cells knocked
out for USP11 using CRISPR/Cas9 technology (HZGH000494c002) were obtained
from Horizon Discovery. Pten+/+ and Pten-/- SV40 T-Ag–transformed MEFs are
previously described43. p85-/- MEFs were kindly provided by L.C. Cantley. All cell
lines were independently validated by short tandem repeat DNA fingerprinting and
chromosomal analysis by the Characterized Cell Line Facility and the Molecular
Cytogenetics Core at the MD Anderson Cancer Center.
siRNA and shRNA. All the sources of siRNA duplexes and shRNA constructs used
are shown in Supplementary Table 1 and Supplementary Data 1.
Antibodies. The antibodies used in the study were anti-PI(3,4,5)P3 (1:200 for
immunofluorescence; Z-P345, Echelon Biosciences); anti-PTEN (1:100 for immu-
nofluorescence, 1:200 for immunohistochemistry; ABM-2052, Cascade); anti-
USP11 (1:100 for immunofluorescence; KG403, Cosmo Bio); anti-FOXO1 (1:200
for immunofluorescence; 04–1005, Millipore); anti-FOXO1 (1:800 for immuno-
histochemistry; ab52857, Abcam); anti-FOXO3 (1:800 for immunohistochemistry;
12829, Cell Signaling); anti-FOXO1 (1:50 for ChIP assay; ab39670, Abcam); anti-
Ki-67 (1:200 for immunohistochemistry; RM-9106, Lab Vision); anti-SV40 T Ag
(1:100 for immunohistochemistry, 554149, BD Pharmingen); anti-SMA (1:200 for
immunohistochemistry; ab7817, Abcam); and anti-P-AKT (1:500 for immuno-
histochemistry; 9271, Cell Signaling). The following antibodies were used for
immunoblotting: anti-PTEN (1:1000, 9559), anti-P-AKT (pS473; 1:1000, 9271),
anti-P-AKT (pT308; 1:1000, 2965), anti-AKT (pan; 1:1000, 4685), anti-P-FOXO1
(pS256; 1:1000, 9461), anti-FOXO1 (1:1000, 2880), anti-FOXO3a (1:1000; 12829),
anti-P-GSK3α (1:1000, 9331), anti-Acetylated lysine (1:1000, 9441), anti-N-
Cadherin (1:1000, 4061), and anti-Myc tag (1:5000, 2276) from Cell Signaling; anti-
USP11 (1:1000, ab109232), anti-OTUD3 (1:2000, ab107646), anti-GLUT1 (1:1000,
ab40084), and anti-Lamin B1 (1:2000, ab16048) from Abcam; anti-USP13 (1:1000,
A302-762) and anti-HAUSP (1:5000, A300-033A) from Bethyl Laboratories; anti-
Actin (1:10000, A2228), anti-α-Tubulin (1:5000, T8203), anti-Hsp90 (1:1000,
H1775), and anti-Flag (1:5000, F1804) from Sigma; anti-GSK3α/β (1:1000, 368662)
from Calbiochem; anti-SIRT1 (1:1000, sc-15404) from Santa Cruz; and anti-Poly-
ubiquitylated protein (1:1000, PW8805) from Biomol.
AlphaScreen assay. Cells were seeded onto 96-well plates at a density of 2 × 103
cells/well, transfected with 67 mouse DUB siGENOME SMARTpool siRNA library
using the Dharmafect I siRNA transfection reagent (Supplementary Data 1),
starved overnight, and stimulated with 100 nM insulin for 15 m. Cells were col-
lected and cell lysis was prepared according to the manufacturer’s instructions. All
AlphaScreen assays were performed in triplicate with white ½ Areaplate-96 plates
(PerkinElmer). For the detection of phosphorylated AKT proteins, anti-P-AKT-
coated AlphaScreen SureFire P-AKT1 (pT308) and P-AKT1/2/3 (pS473) acceptor
beads (PerkinElmer) were used. Briefly, 16 μl of cell lysate and acceptor beads in
buffer (20 μl) were transferred to each well and incubated for 2 h at room tem-
perature. A total of 8 μl of a 1:50 dilution of the streptavidin donor beads was then
added to give a final volume of 44 μl, and the mixture was incubated at room
temperature for 2 h. All additions and incubations were made in subdued lighting
conditions due to the photosensitivity of the beads, and finally, the assay plates
were read with a Synergy Neo multi-mode microplate reader (Biotek).
Lipid extraction and quantification of PI(3,4,5)P3. Cells (1 × 107) were incu-
bated with cold 0.5 M trichloroacetic acid for 5 m, centrifuged, and resuspended in
5% trichloroacetic acid and 1 mM ethylenediaminetetraacetic acid (EDTA). After
removing neutral and acidic lipids, chloroform and 0.1 M HCl were added to the
supernatant followed by centrifugation to separate organic and aqueous phases.
The organic phase was dried in a vacuum dryer. PI(3,4,5)P3 was quantified using
the PI(3,4,5)P3 Mass ELISA kit (Echelon Biosciences). Absorbance was measured
at 450 nm using an iMark microplate reader (Bio-Rad).
In vivo and in vitro deubiquitination assays. 293T cells were transfected with
pCMV-Flag-USP11WT or pCMV-Flag-USP11C318S, pcDNA3-HA-Ubiquitin and
pRK5-Myc-PTEN and treated with 10 μMMG132 (Sigma) for 4 h. Cells were lysed
in 1% sodium dodecyl sulfate (SDS), boiled, and sonicated before diluting in RIPA
[25 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1 mM EDTA, 1% NP40, 1% sodium
deoxycholate, and 0.1% SDS]. The lysates were immunoprecipitated with anti-Myc
tag antibody. The resulting immunoprecipitates were washed five times with RIPA
buffer and subjected to immunoblotting with anti-HA (1:1000, MMS-101P; Cov-
ance). Alternatively, cells were lysed by incubation for 10 min at 95 °C with two
volumes of tris-buffered saline (TBS) containing 2% SDS. After adding eight
Fig. 4 USP11 suppresses cancer cell biology in a PTEN-dependent manner. a Growth curves of HAP1 cells knocked out (KO) for USP11 using CRISPR/Cas9
technology expressing wild-type (WT) or catalytically inactive C318S (CS) mutant of USP11. n= 3. **p < 0.01, ***p < 0.001, Cont. vs. USP11WT; $$p < 0.01,
$$$p < 0.001, USP11WT vs. USP11CS; #p < 0.05, ##p < 0.01, Cont. vs. USP11CS. b Cell-invasion assays of HAP1 cells KO for USP11 expressing WT or CS mutant
of USP11 in the presence of mitomycin C (5 μg ml−1) (top). The number of invaded cells per field was quantified (bottom). n= 3. c The rates of glucose
uptake, lactate production, and glutamine consumption of HAP1 cells KO for USP11 expressing WT or CS mutant of USP11 were measured and normalized
to cell number. n= 3. d Growth curves of PC3 PTENWT and PC3 PTEN-/- cells expressing USP11. n= 3. *p < 0.05, **p < 0.01, PTENWT; Cont. vs. PTENWT;
USP11; n.s., non-significant, PTEN-/-;Cont. vs. PTEN-/-;USP11. e Cell-invasion assays of PC3 PTENWT and PC3 PTEN-/- cells ectopically expressing USP11 in
the presence of mitomycin C (5 μgml−1) (top). The number of invaded cells per field was quantified (bottom). n= 3. f The rates of glucose uptake, lactate
production, and glutamine consumption of PC3 PTENWT and PC3 PTEN-/- cells ectopically expressing USP11 were measured and normalized to cell number.
n= 3. g Growth curves of PC3 PTENWT and PC3 PTEN-/- cells expressing USP11 shRNA. n= 3. *p < 0.05, ***p < 0.001, PTENWT;shCont. vs. PTENWT;shUSP11; n.
s., non-significant, $$$p < 0.001, PTEN-/-;shCont. vs. PTEN-/-;shUSP11. h Cell-invasion assays of PC3 PTENWT and PC3 PTEN-/- cells expressing USP11 shRNA in
the presence of mitomycin C (5 μgml−1) (top). The number of invaded cells per field was quantified (bottom). n= 3. i The rates of glucose uptake, lactate
production, and glutamine consumption of PC3 PTENWT and PC3 PTEN-/- cells expressing USP11 shRNA were measured and normalized to cell number. n= 3.
Scale bars, 100μm. Error bars represent ± SEM. p Value was determined by Student’s t test (n.s., non-significant; *p < 0.05, **p < 0.01, ***p < 0.001)
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Fig. 5 USP11 is downregulated and correlates with PTEN in human cancers. a, b USP11 expression in human prostate (a) and breast (b) cancers using a
previously published microarray database. Stephenson’s CaP, prostate carcinoma (ref.44, n= 97); Taylor’s CaP (GEO: GSE21032, n= 179); Liu’s BCa,
breast carcinoma (GEO: GSE22820, n= 176). The line in the middle, upper end, and lower end of the boxplot represents the mean, upper, and lower
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by log-rank (Mantel–Cox) test. HR, hazard ratio. d Fluorescence in situ hybridization (FISH) analysis of PTEN in human prostate (left, n= 116) and TNBC
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PTEN IHC and PTEN FISH was determined by the PASS Pearson Chi-square test. e IHC analysis of USP11 and PTEN in human prostate (top, n= 99) and
TNBC (bottom, n= 86) tumor samples (left). Scale bars, 50μm. Correlation between USP11 and PTEN protein levels was determined by the PASS Pearson
Chi-square test (right). r, correlation coefficient. TNBC, triple-negative breast cancer
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volumes of 1% Triton X-100 in TBS, the lysates were briefly sonicated and then
incubated with protein G-agarose beads (Pierce). The beads were removed by
centrifugation, and the lysates were immunoprecipitated with anti-PTEN antibody
(Cell Signaling). The immunoprecipitates were washed with 0.5 M LiCl in TBS and
then subjected to immunoblotting with anti-Ubiquitin (BioMol). For the
in vitro deubiquitination assay of PTEN, His-PTEN proteins were incubated with
50 μg ml−1 of rabbit E1 (Boston Biochem), 50 μg ml−1 of UbcH5 (Boston Bio-
chem), 4 μg ml−1 of ubiquitin aldehyde (Calbiochem), along with an ATP regen-
erating system (7.5 mM creatine phosphate, 1 mM ATP, 1 mM MgCl2, 0.1 mM
EGTA, rabbit creatine phosphokinase type I (30Uml−1) (Sigma)), ubiquitin
(10 mgml−1) (Sigma), and 5 μg cell lysate of DU145 to a final reaction volume of
20 μl for 1 h at room temperature. In vitro translated USP11 was then added into
the reaction mixture for the indicated times, and the extent of ubiquitination of
PTEN was analyzed by sodium dodecyl sulphate-polyacrylamide gel electrophor-
esis and immunoblotting.
Real-time quantitative reverse transcription PCR. Total RNA was isolated with
Trizol reagent (Invitrogen) and reverse-transcribed with the PrimeScript reverse
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transcriptase (Takara). Expression of specific mRNAs was determined with a
LightCycler (Roche) using the SYBR green PCR master mix (Roche). All the
sources of real-time quantitative reverse transcription PCR primers used are listed
in Supplementary Table 2.
Luciferase reporter assay. Cells were transfected with pUSP11-Luc (Genecopeia)
or two independent FOXO-binding mutants, pUSP11-Luc (Mut1 or Mut2) (Sup-
plementary Table 3) together with a secreted alkaline phosphatase (SEAP)
expression vector (Genecopeia) to normalize the transfection efficiency. Cell
extracts were processed using the Secrete-Pair Dual Luminescence Assay Kit
(Genecopeia) according to the manufacturer’s instructions. Luciferase activity was
measured with a Synergy Neo multi-mode microplate reader. Gaussia luciferase
values were normalized to SEAP activity.
Chromatin immunoprecipitation assays. ChIP assays were performed using the
ChIP kit (Millipore) with the usage of anti-FOXO1 antibody (1:50; ab39670,
Abcam) as described67. Briefly, cells were fixed with 1% formaldehyde and lysed
with lysis buffer (50 mM Tris-HCl (pH 8.0), 10 mM EDTA, 1% SDS, 0.2 mM
phenylmethane sulfonyl fluoride, 1 μg ml−1 aprotinin, 2.5 μg ml−1 leupeptin,
1 μg m−1 pepstatin). The cell lysates were sonicated with a Bioruptor machine
(Diagenode) for 12–18 min with cycles of 30 s pulses and 1 min pauses to shear the
DNA to a final size of 200–500 bp. After preclearing with protein A beads
(Repligen) for 1–2 h, the antibody was added and incubated overnight at 4 °C.
Protein A-agarose beads were added and incubated for 1–2 h. The complex was
washed with low-salt buffer, high-salt buffer, and LiCl buffer and twice with Tris-
EDTA buffer, followed by elution in a buffer containing 1% SDS and 0.1 M
NaHCO3. The crosslinks were reversed, and the DNA was purified with a QIA-
quick PCR purification kit (Qiagen) and subjected to analysis by real-time qPCR.
Chromatin immunoprecipitates for proteins were amplified by qPCR, normalized
to input, and calculated as percentage of input. The PCR primers for ChIP assays
are listed in Supplementary Table 4.
Cellular proliferation, migration, and transformation assays. Typically, cell
proliferation, migration, and oncogenic transformation assays were performed as
described8,68,69. Briefly, growth curves were generated by seeding 2 × 104 cells into
a 12-well plate. Plates were stained with crystal violet at each indicated time point.
The dye was extracted with 10% acetic acid followed by plate reading at 595 nm in
an iMark Plate Reader (Bio-Rad). For directional cell migration assay, cells were
grown to full confluence, serum-starved overnight, and a uniform scratch was
made along the center of the plate using a pipet tip. Detached cells were washed out
twice, and the remaining cells were then incubated for 12 or 24 h in the presence of
mitomycin C (5 μg ml−1). Images of cell monolayers were taken at the time
indicated under the microscope. The wound wideness was calculated by measuring
the mean distance between the margins of the wound in randomly selected fields,
directly on photographs. Cell migration was quantified by calculating the area of
wound at time points t= 0 (time of wound) and t= 12 or 24 (12 or 24 h after
wound). For the transformation assay, primary USP11+/Y and USP11-/Y MEFs (P1)
were plated at a density of 6 × 105 cells into a 10 cm dish and infected with
retroviral particles prepared from 293T cells expressing pWZL-E1a (Addgene) with
pBabe-Ha-ras (Addgene), pMSCV-SV40 T-Ag (Addgene) or pSUPER Retro-
p19ARF and –p16INK4a shRNAs (kindly provided by M. Serrano). Foci were scored
after 3 weeks by crystal violet staining.
Glucose uptake, lactate production, and glutamine consumption. To measure
glucose uptake and extracellular lactate, 1–2 × 105 cells were seeded into a six-well
plate. Twelve hours later, the medium was replaced with 3 ml of complete medium
and supernatants were collected 24 h later and analyzed for glucose and lactate
content using the Glucose colorimetric assay kit II (Bio Vision) and the Lactate
colorimetric assay kit II (Bio Vision), respectively, according to the manufacturer’s
instructions. Glucose consumption was extrapolated by subtracting the measured
glucose concentrations in the medium from the original glucose concentration
(25 mM). Both glucose consumption and lactate production are normalized to the
total cell number. To measure glutamine consumption, 1–2 × 105 cells were seeded
onto six-well plates. Twelve hours later, the medium was replaced with 3 ml of
complete medium and supernatants were collected 24 h later and analyzed for
lactate content and glutamine consumption using the Glutamine colorimetric assay
kit (Bio Vision), according to the manufacturer’s instructions. Glutamine con-
sumption was extrapolated by subtracting the measured glutamine concentrations
in the medium from the original glutamine concentration (25 mM). The rates of
glucose uptake, lactate production, and glutamine consumption were normalized to
cell number.
Immunofluorescence analysis. For PI (3,4,5)P3, PTEN, USP11, or FOXO1
immunofluorescence staining, cells were incubated with anti-PI(3,4,5)P3 antibody,
anti-PTEN, anti-USP11, or anti-FOXO1. Cells were then washed and incubated
with Cy3 anti-mouse secondary antibody (1:5000; Jackson ImmunoResearch)
for 1 h. Slides were then mounted in Vectashield containing 4′,6-diamidino-2-
phenylindole (Vector Lab). Immunofluorescence images were generated using a
Leica DMI 3000B fluorescence microscope (Leica).
Immunohistochemistry analysis. Mouse tissue paraffin sections were depar-
affinized, rehydratred, and subjected to heat-mediated antigen retrieval in citrate
buffer. After blocking the endogenous peroxidase by 3% H2O2, sections were
blocked in 10% goat serum and incubated with the following antibodies: anti-
PTEN, anti-USP11, anti-P-AKT, anti-Ki-67, anti-SV40 T Ag, and anti-SMA. The
signal was detected with biotinylated horseradish peroxidase reagent (Vectastain
ABC kit, Vector Lab) and DAB (Vector Lab) according to the manufacturer’s
instructions. The sections were counter-stained with hematoxylin. The images were
acquired with a Leica DM1000 microscope. The stained slides were scanned on
Automated Cellular Image System III (Dako, Denmark) for quantification by
digital image analysis. The quantification of staining density was performed using
an ImagePro software (Media Cybernetics) and calculated based on the average
staining intensity and the percentage of positively stained cells.
Human tumor tissue microarray analysis. The multiple prostate carcinoma
(PR483 and PR803) tumor TMAs were obtained from US Biomax. The study
cohort comprised TNBC consecutively ascertained at the MD Anderson Cancer
Center (MDACC). All biopsies were evaluated at MDACC, and the histological
diagnosis was based on established criteria. Human TMA work was performed in
accordance with Institutional Review Board approval at MDACC. TMA slides were
incubated with antibodies against PTEN, USP11, FOXO1, or FOXO3 and a biotin-
conjugated secondary antibody and then incubated with an
avidin–biotin–peroxidase complex. Visualization was performed using 3-amino-9-
ethylcarbazole (AEC) chromogen. The TMA cores were scored by two pathologists
(W. Xia and Y. Wu) blind to cancer outcomes. According to histologic scoring, the
intensity of staining was ranked into one of the four following groups: high (+++),
medium (++), low (+), and negative (-).
Fluorescence in situ hybridization analysis. FISH assays on TMAs were per-
formed using PTEN/Con 10 FISH probes from Empire Genomics. The slides were
hybridized with the FISH probes according to the manufacturer’s instructions with
slight modifications as previously described70. Briefly, FISH probes were denatured
at 75 °C for 5 min and held at 37 °C for 10–30 min until 10 μl of probe was applied
to each sample slide. Slides were coverslipped and hybridized overnight at 37 °C in
the ThermoBrite hybridization system (Abbott Molecular). The post-hybridization
wash was with 2 × SSC/0.2% Tween-20 at 73 °C for 3 min followed by a brief water
rinse. Slides were air dried and then counterstained with Vectashield containing
4′,6-diamidino-2-phenylindole (Vector Lab). The slides were then examined under
a fluorescence microscope (Nikon 80i) equipped with multiple filters, and signals
were manually counted in 50 cells for each TMA core by two geneticists (A.
Multani and S. Pathak) blind to PTEN immunohistochemistry results and cancer
outcomes.
Fig. 7 FOXO activates the expression of USP11, thereby upregulating PTEN. a Lysates from DU145 cells expressing SIRT1 shRNA treated with 25 μM
resveratrol for 16 h were immunoprecipitated (IP) with anti-FOXO1, and the resulting immunoprecipitates were subjected to immunoblotting (IB).
b, c Lysates from DU145 cells expressing two independent shRNAs against SIRT1 (b) or FOXO1 (c) treated with 25 μM resveratrol for 16 h were subjected
to IB. d Lysates from DU145 cells pre-treated with 25 μM resveratrol for 16 h followed by treatment with cycloheximide (CHX, 100 μg ml−1) for the
indicated times were subjected to IB. n= 3, p value was determined by ANOVA. e Lysates from DU145 cells expressing USP11 shRNA treated with 25 μM
resveratrol for 16 h were subjected to IB. f Lysates from DU145 cells expressing USP11 shRNA and treated with 25 μM resveratrol (Resv.) for 16 h and 10
μM MG132 for the last 4 h before harvesting were immunoprecipitated with anti-PTEN, and the resulting immunoprecipitates were subjected to IB.
g Luciferase reporter analysis of the USP11 promoter in NIH-3T3 cells expressing constitutive, active FOXO1T24A,T256A,S319A or FOXO3T32A,S253A,S315A.
n= 3. h Immunofluorescence analysis of FOXO1 in PTEN-/- HCT116 cells treated with 5 μM psammaplysene A (PsA) for 24 h. Scale bars, 10μm. i Lysates
from PTEN+/+ HCT116 cells treated with 5 μM PsA for 24 h were subjected to IB. j Immunohistochemical analysis of FOXO3 or FOXO1 and USP11 in human
prostate (left, n= 37) and TNBC (right, n= 68) tumor samples. Scale bars, 50μm. Correlation between FOXO localization and USP11 protein levels was
determined by the PASS Pearson Chi-Square test (right). Error bars represent ± SEM. p Value was determined by Student’s t test (*p < 0.05, **p < 0.01,
***p < 0.001). TNBC, triple-negative breast cancer
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Cancer biostatistical analysis. Relative expression levels of USP11 in prostate or
breast cancer patients compared to normal samples were analyzed using previously
published microarray database (Stephenson’s prostate carcinoma (ref.44, n= 97);
Taylor’s prostate carcinoma (GEO: GSE21032, n= 179); Liu’s breast carcinoma
(GEO: GSE22820, n= 176)). For correlation analysis between USP11 and prognosis,
Kaplan–Meier plotting and log-rank test were performed using a publicly accessible
online tool KM Plotter (http://kmplot.com)31. Patients were divided into two classes
based on USP11 expression: the high- and low–USP11 groups were split based on
the median value calculated across the entire dataset to generate two groups of equal
size. Sample size: RFS, relapse-free survival, n= 618; OS, overall survival, n= 241.
Mouse allograft tumor model. Cells (0.5 × 106 cells per site) in suspension were
mixed with equal volumes of Matrigel (BD Biosciences) and injected
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subcutaneously into 8-week-old male Swiss nu/nu mice (Taconic Biosciences).
Measurement of tumor size was performed every other day, and the tumor volume
was estimated using the formula: volume= length × width2 × 0.526.
MRI imaging. Mice were imaged with abdominal MRI by the MD Anderson
Cancer Center Small Animal Imaging Facility. Mice were anesthetized with
2% isoflurane–air mixture. Images were obtained with a 4.7T Brucker MR scanner
(40-cm horizontal bore; Brucker Biospin MRI). A double-tuned volume radio-
frequency coil was used to scan the abdominal region of the mice. Axial T2-
weighted images were acquired using a fast spin-echo sequence with the following
parameters: repetition time/effective echo time, 4000/60 ms; echo spacing, 15 ms;
number of echoes, 8; field of view, 30 mm × 30 mm; matrix, 128 × 128; slice
thickness, 1 mm; slice spacing, 0.25 mm; number of slices, 17 and number of scans,
4 (total scan time was approximately 4 m).
Statistical analysis. Data are expressed as the mean ± SEM of the values from the
independent experiments performed, as indicated in the corresponding figure
legends. The numbers of biological replicates, and what they represent, are indi-
cated in each figure legend. Statistical analysis was performed with SPSS V.20.0 and
GraphPad Prism 6. Two-tailed Student’s t tests were used for single comparison,
and analysis of variance (ANOVA) with Bonferroni post-hoc tests was used for
multiple comparisons unless otherwise specified. The correlation coefficients were
calculated by the PASS Pearson Chi-Square test. p Values below 0.05 were con-
sidered statistically significant.
Reporting summary. Further information on the experimental design is available
in the Nature Research Reporting Summary linked to this article.
Data availability
All relevant data are included in the manuscript and available from the authors
upon reasonable request. Uncropped gels and blots are available in Supplemen-
tary Information (Supplementary Figure 11). A reporting summary for this article
is available as a Supplementary Information file.
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